165
Participants
Start Date
September 14, 2023
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2027
IKS014
IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent.
RECRUITING
Macquarie University, Sydney
RECRUITING
Concord Repatriation General Hospital Medical Oncology Clinical Trials Unit, Concord
RECRUITING
Westmead Hospital, Westmead
RECRUITING
Alfred Health, Melbourne
RECRUITING
Peninsula & South Eastern Haematology and Oncology Group (PSEHOG), Frankston
RECRUITING
Linear Clinical Research, Nedlands
NOT_YET_RECRUITING
Tennessee Oncology, Nashville
NOT_YET_RECRUITING
Hoag Memorial Hospital Presbyterian, Newport Beach
NOT_YET_RECRUITING
Dana Farber Cancer Institute, Boston
NOT_YET_RECRUITING
Auckland City Hospital, Auckland
NOT_YET_RECRUITING
National Cancer Centre Singapore, Singapore
NOT_YET_RECRUITING
Tan Tock Seng Hospital, Singapore
Lead Sponsor
Iksuda Therapeutics Ltd.
INDUSTRY